B Fekete1, K Werlenius2, C Örndal3, B Rydenhag1,4. 1. Department of Clinical Neuroscience and Rehabilitation, The Sahlgrenska Academy, Institute of Neuroscience and Physiology, University of Göteborg, Göteborg, Sweden. 2. Department of Oncology, Sahlgrenska University Hospital, The Sahlgrenska Academy, University of Göteborg, Göteborg, Sweden. 3. Department of Pathology, Sahlgrenska University Hospital, The Sahlgrenska Academy, University of Göteborg, Göteborg, Sweden. 4. Department of Neurosurgery, Sahlgrenska University Hospital, The Sahlgrenska Academy, University of Göteborg, Göteborg, Sweden.
Abstract
OBJECTIVES: To address in a retrospective and population-based study prognostic factors for survival time after diagnosis and surgery for glioblastoma multiforme (GBM). MATERIAL AND METHODS: During the study period, 430 patients were identified at the multidisciplinary team conferences as newly diagnosed GBM, 201 of these were considered not to benefit from surgery, and thus, a total of 229 consecutive adult patients with GBM were operated between January 2004 and December 2008 at Sahlgrenska University Hospital and were retrospectively analyzed. Potential predictors of survival were statistically analyzed using Poisson regression models. RESULTS: Median survival was 0.73 years. Multivariable analysis showed the following factors to positively influence survival: younger age at surgery, secondary tumor genesis, unifocal tumor location (vs multifocal), resection (vs biopsy only), radiotherapy, and combination of radiotherapy and chemotherapy. CONCLUSION: This population-based study supports the importance of surgery instead of biopsy only, followed by radiotherapy and chemotherapy, a finding which has also been stated in earlier non-population-based reports. However, it is obvious that the solution is not just surgical radicality followed by optimal oncological treatment. It is of great importance to seek further subclassifications, biomarkers, and new treatment modalities to make a significant change in survival for individuals.
OBJECTIVES: To address in a retrospective and population-based study prognostic factors for survival time after diagnosis and surgery for glioblastoma multiforme (GBM). MATERIAL AND METHODS: During the study period, 430 patients were identified at the multidisciplinary team conferences as newly diagnosed GBM, 201 of these were considered not to benefit from surgery, and thus, a total of 229 consecutive adult patients with GBM were operated between January 2004 and December 2008 at Sahlgrenska University Hospital and were retrospectively analyzed. Potential predictors of survival were statistically analyzed using Poisson regression models. RESULTS: Median survival was 0.73 years. Multivariable analysis showed the following factors to positively influence survival: younger age at surgery, secondary tumor genesis, unifocal tumor location (vs multifocal), resection (vs biopsy only), radiotherapy, and combination of radiotherapy and chemotherapy. CONCLUSION: This population-based study supports the importance of surgery instead of biopsy only, followed by radiotherapy and chemotherapy, a finding which has also been stated in earlier non-population-based reports. However, it is obvious that the solution is not just surgical radicality followed by optimal oncological treatment. It is of great importance to seek further subclassifications, biomarkers, and new treatment modalities to make a significant change in survival for individuals.
Authors: Florien W Boele; Charles W Given; Barbara A Given; Heidi S Donovan; Richard Schulz; Jason M Weimer; Jan Drappatz; Frank S Lieberman; Paula R Sherwood Journal: Cancer Date: 2016-10-27 Impact factor: 6.860
Authors: Florien W Boele; Jason Weimer; Amir H Zamanipoor Najafabadi; Louise Murray; Charles W Given; Barbara A Given; Heidi S Donovan; Jan Drappatz; Frank S Lieberman; Paula R Sherwood Journal: Cancer Nurs Date: 2021-09-30 Impact factor: 2.760
Authors: Birgit C Weyhenmeyer; Janis Noonan; Maximilian L Würstle; Frank A Lincoln; Grainne Johnston; Markus Rehm; Brona M Murphy Journal: Oncotarget Date: 2016-09-20
Authors: Anna Wenger; Katja Werlenius; Alexander Hallner; Fredrik Bergh Thorén; Dan Farahmand; Magnus Tisell; Anja Smits; Bertil Rydenhag; Asgeir S Jakola; Helena Carén Journal: Neoplasia Date: 2017-12-01 Impact factor: 5.715